Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Other Non-Current Liabilities (2017 - 2026)

Bioceres Crop Solutions' Other Non-Current Liabilities history spans 10 years, with the latest figure at $1.0 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a N/A change, with the full-year FY2025 number at $1.3 million, up 3.53% from a year prior.
  • Other Non-Current Liabilities hit $1.0 million in Q1 2026 for Bioceres Crop Solutions, down from $1.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for BIOX hit a ceiling of $1.3 million in Q2 2025 and a floor of $603022.0 in Q2 2022.
  • Historically, Other Non-Current Liabilities has averaged $1.0 million across 5 years, with a median of $1.0 million in 2026.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 47.88% in 2023 and later increased 3.53% in 2025.
  • Tracing BIOX's Other Non-Current Liabilities over 5 years: stood at $603022.0 in 2022, then skyrocketed by 47.88% to $891769.0 in 2023, then surged by 40.81% to $1.3 million in 2024, then increased by 3.53% to $1.3 million in 2025, then fell by 23.08% to $1.0 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for BIOX at $1.0 million in Q1 2026, $1.3 million in Q2 2025, and $1.3 million in Q2 2024.